​

SAB Biotherapeutics (SABS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

SABS Stock Forecast

SAB Biotherapeutics (SABS) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $7.00 and a low of $7.00. This represents a 131.02% increase from the last price of $3.03.

- $1 $2 $3 $4 $5 $6 $7 High: $7 Avg: $7 Low: $7 Last Closed Price: $3.03

SABS Stock Rating

SAB Biotherapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (83.33%), 1 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 1 5 0 Strong Sell Sell Hold Buy Strong Buy

SABS Price Target Upside V Benchmarks

TypeNameUpside
StockSAB Biotherapeutics131.02%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$7.00$7.00
Last Closing Price$3.03$3.03$3.03
Upside/Downside-131.02%131.02%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2515---6
Sep, 2514---5
Aug, 2514---5
Jul, 2514---5
Jun, 2514---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 17, 2025Leerink Partners$7.00$2.58171.32%131.02%
Jun 07, 2024Kumaraguru RajaLoop Capital Markets$8.00$2.84181.69%164.03%
Apr 02, 2024Edward WhiteH.C. Wainwright$6.00$4.2939.86%98.02%
Aug 11, 2022Chardan Capital$3.00$1.12167.86%-0.99%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 09, 2024Craig-HallumBuyinitialise
Aug 27, 2024OppenheimerOutperforminitialise
Jun 07, 2024Brookline CapitalBuyinitialise
Apr 02, 2024H.C. WainwrightBuyBuyhold
Aug 11, 2022Chardan CapitalBuyBuyhold
May 13, 2022Chardan CapitalBuyBuyhold

Financial Forecast

EPS Forecast

$-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.64$-0.43$-7.64-----
Avg Forecast$-1.93$-3.45$-4.22$-3.68$-3.09$-2.57$-2.35$-2.16
High Forecast$-1.63$-3.26$-3.66$-3.48$-1.01$-1.12$-1.71$-2.16
Low Forecast$-2.63$-3.93$-5.00$-3.92$-5.49$-4.53$-3.00$-2.16
Surprise %-66.84%-87.54%81.04%-----

Revenue Forecast

$0 $18M $36M $54M $72M $90M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$60.88M$23.90M$2.24M-----
Avg Forecast$67.89M$27.64M$1.30M$1.32M$800.00K$1.67M$1.75M$2.00M
High Forecast$87.07M$30.57M$1.90M$1.69M$800.00K$1.67M$1.75M$2.00M
Low Forecast$60.00M$26.44M$689.39K$1.19M$800.00K$1.67M$1.75M$2.00M
Surprise %-10.33%-13.50%72.23%-----

Net Income Forecast

$-45M $-37M $-29M $-21M $-13M $-5M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-17.44M$-18.74M$-42.19M-----
Avg Forecast$-10.63M$-19.05M$-23.90M$-20.43M$-17.95M$-15.61M$-12.99M$-11.93M
High Forecast$-9.02M$-17.98M$-20.21M$-19.22M$-5.58M$-6.18M$-9.43M$-11.93M
Low Forecast$-14.53M$-21.68M$-27.59M$-21.64M$-30.31M$-25.03M$-16.55M$-11.93M
Surprise %64.12%-1.62%76.54%-----

SABS Forecast FAQ

Is SAB Biotherapeutics stock a buy?

SAB Biotherapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that SAB Biotherapeutics is a favorable investment for most analysts.

What is SAB Biotherapeutics's price target?

SAB Biotherapeutics's price target, set by 6 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $7 at the low end to $7 at the high end, suggesting a potential 131.02% change from the previous closing price of $3.03.

How does SAB Biotherapeutics stock forecast compare to its benchmarks?

SAB Biotherapeutics's stock forecast shows a 131.02% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for SAB Biotherapeutics over the past three months?

  • October 2025: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is SAB Biotherapeutics’s EPS forecast?

SAB Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-3.68, marking a -51.83% decrease from the reported $-7.64 in 2023. Estimates for the following years are $-3.09 in 2025, $-2.57 in 2026, $-2.35 in 2027, and $-2.16 in 2028.

What is SAB Biotherapeutics’s revenue forecast?

SAB Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $1.32M, reflecting a -40.90% decrease from the reported $2.24M in 2023. The forecast for 2025 is $800K, followed by $1.67M for 2026, $1.75M for 2027, and $2M for 2028.

What is SAB Biotherapeutics’s net income forecast?

SAB Biotherapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-20.429M, representing a -51.58% decrease from the reported $-42.194M in 2023. Projections indicate $-17.946M in 2025, $-15.605M in 2026, $-12.994M in 2027, and $-11.926M in 2028.